Depression is a prevalent, complex, and highly debilitating disease. The full comprehension
of this disease is still a global challenge. Indeed, relapse, recurrency, and therapeutic …

Psychedelics have inspired new hope for treating brain disorders, as they seem to be unlike
any treatments currently available. Not only do they produce sustained therapeutic effects …

The psychedelic psilocybin is being investigated for the treatment of depression and anxiety.
Unclear is whether antidepressant treatments interact with psilocybin. The present study …

In addition to producing profound subjective effects following acute administration,
psychedelic compounds can induce beneficial behavioral changes relevant to the treatment …

Psychedelics make up a group of psychoactive compounds that induce hallucinogenic
effects by activating the serotonin 2A receptor (5-HT2AR). Clinical trials have demonstrated …

Therapeutic deficiencies with monoaminergic antidepressants invites the need to identify
and develop novel rapid-acting antidepressants. Hitherto, ketamine and esketamine are …

Major depressive disorder (MDD) affects millions of people worldwide and is a leading
cause of disability. Several theories have been proposed to explain its pathological …

The interest in psilocybin as a therapeutic approach has grown exponentially in recent
years. Despite increasing access, there remains a lack of practical guidance on the topic for …

Omega-3 polyunsaturated fatty acids (PUFAs) can play important roles in maintaining
mental health and resistance to stress, and omega-3 PUFAs supplementation can display …

Opioid receptors are widely distributed throughout the brain and play an essential role in
modulating aspects of human mood, reward, and well-being. Accumulating evidence …